1446021-66-4 Usage
General Description
(3aR,5S,6aS)-tert-butyl 5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is a chemical compound with a molecular formula of C14H25NO2. It is a derivative of cyclopenta[c]pyrrole, which has potential pharmaceutical and medicinal applications. The tert-butyl group is a common protective group used in organic synthesis to prevent unwanted reactions or to enhance the properties of the molecule, while the methylamino group can be found in various pharmaceuticals and biologically active compounds. (3aR,5S,6aS)-tert-butyl 5-(methylamino)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate is an ester, which means it can be hydrolyzed to release the corresponding carboxylic acid and alcohol. The presence of a carboxylic acid group and an amino group make this compound a potential candidate for drug development or medicinal chemistry applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1446021-66-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,4,6,0,2 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1446021-66:
(9*1)+(8*4)+(7*4)+(6*6)+(5*0)+(4*2)+(3*1)+(2*6)+(1*6)=134
134 % 10 = 4
So 1446021-66-4 is a valid CAS Registry Number.
1446021-66-4Relevant articles and documents
JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE
-
, (2022/01/24)
-
BISULFATE OF JANUS KINASE (JAK) INHIBITOR AND PREPARATION METHOD THEREFOR
-
Paragraph 0016; 0018; 0019, (2016/05/10)
The present invention relates to a bisulfate of a Janus kinase (JAK) inhibitor and a preparation method therefor. More specifically, the present invention relates to a (3aR,5s,6aS)-N-(3-methoxyl-1,2,4-thiadiazole-5-group)-5-(methyl(7H-pyrrolo[2,3-d]pyrimidine-4-group)amino)hexahydrocyclopenta[c]pyrrole-2(1H)-formamide bisulfate shown in the formula (I), a preparation method therefor, and an application thereof. The bisulfate shown in the formula (I) can be well suitable as a Janus kinase (JAK) inhibitor in clinical work for treating rheumatism or rheumatoid arthritis.
SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
-
, (2015/07/07)
The present invention provides new heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of JAK-mediated diseases. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated diseases.
